ETFs Genome & Company

A314130

KR7314130006

Biotechnology & Medical Research

End-of-day quote Korea S.E. 24/08/2026			5-day change	1st Jan Change
4,240.00 ^KRW	+0.83%		-8.23%	-38.37%

04-13	Genome & Company announced that it has received KRW 6.99999414 billion in funding	CI
04-03	Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding	CI

ETFs positioned on Genome & Company

Name		YTD change	Weight	AuM
DIMENSIONAL EMERGING MARKETS CORE EQUITY 2 ETF - USD		+19.50%	-.--%	9,273 M€

Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.

Employees

Sector

Biotechnology & Medical Research

More about the company